MannKind | MNKD - Operating Expenses


MannKind reported $104.44M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Adma Biologics USD 71.95M 7.75M Jun/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Insmed USD 606.26M 79.46M Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 25.15M 17.72M Sep/2026
MannKind USD 104.44M 5.77M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Novavax USD 126.2M 23.62M Dec/2025
Novo Nordisk DKK 6.96B 30.25B Jun/2026
Pfizer USD 89B 3.81B Sep/2026
Sanofi EUR 10.51B 598M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026